Mylan, Company Behind EpiPen, Fought to Keep Cheaper Generic Off Market: Documents | NBC 10 Philadelphia
National & International News
The day’s top national and international news

Mylan, Company Behind EpiPen, Fought to Keep Cheaper Generic Off Market: Documents

    processing...

    NEWSLETTERS

    AP, File
    This Oct. 10, 2013, file photo, shows an EpiPen epinephrine auto-injector, a Mylan product, in Hendersonville, Texas. Mylan, now in the crosshairs over severe price hikes for its EpiPen, said Thursday, Aug. 25, 2016, it will expand programs that lower out-of-pocket costs by as much as half.

    The CEO of Mylan Pharmaceuticals announced the launch of its own cheaper version of the EpiPen this week on the heels of a price hike uproar. But for years, Mylan and its business partners have fought fiercely behind the scenes to block a cheaper generic from hitting the market, NBC New York's I-Team reported.

    Documents reviewed by the I-Team show the Pennsylvania-based drug firm paid for opposition research on a generic EpiPen proposed by Teva, an Israeli pharmaceutical company.

    WATCH: Pippa Middleton Post-Wedding Kiss

    [NATL] WATCH: Pippa Middleton Post-Wedding Kiss

    Pippa Middleton and James Matthews kiss after their wedding at St Mark's Church in Englefield, England, on Saturday, May 20, 2017. Middleton, the sister of Kate, Duchess of Cambridge, married hedge fund manager James Matthews in a ceremony Saturday. Her niece and nephew, Prince George and Princess Charlotte, were in the wedding party, along with sister Kate and princes Harry and William.

    (Published Saturday, May 20, 2017)

    The study concluded the Teva product would have a 93 percent failure rate.

    But experts on research methodology say the study has significant flaws, including the lack of any control group, the lack of any statistical significance, and the fact that study participants were instructed "not to actually manipulate the device or perform the injection."

    In an email to the I-Team, Nina Devlin, a company spokeswoman, defended the integrity of the study, saying it "offered a valid examination" of Teva's product design and how the injector might be used in an emergency.